Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
U.S. STOCKS ON THE MOVE-Macy's, American Eagle, Designer Brands
U.S. STOCKS ON THE MOVE-Copper miners, BKV, Kinetik
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
U.S. STOCKS ON THE MOVE-Lovesac, Hagerty, Biohaven
Biohaven drops as US FDA seeks more BHV-7000 safety data
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
RBC downgrades Biohaven to 'sector perform', shares fall
U.S. STOCKS ON THE MOVE-Williams-Sonoma, Kraft Heinz, Evommune
U.S. STOCKS ON THE MOVE-Revolution Medicines, Abercrombie & Fitch, Williams-Sonoma
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker
U.S. STOCKS ON THE MOVE-Semtech, Donaldson, Meta